Cure Genetics

Next-generation cell and gene therapies for solid tumors and genetic disease

Suzhou, China · Founded 2016 · $77.0M raised

Headquarters
Suzhou
Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$77.0M
Last Round
$60.0M Series BJan 2022
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.

About

Cure Genetics (克睿基因) is a clinical-stage biotechnology company founded in 2016 and headquartered in Suzhou, China, developing next-generation cell and gene therapies for solid tumors and genetic diseases using two proprietary technology platforms. Its AIMS CAR-NKT platform engineers natural killer T cells for superior tumor microenvironment penetration and anti-tumor activity, demonstrated in the first human trial of CAR-NKT therapy for renal cell carcinoma (CGC729). Its VELP AAV platform enables discovery of novel adeno-associated virus serotypes with organ-specific targeting for liver, neurological, cardiac, and kidney diseases, powering a major collaboration with Boehringer Ingelheim.

Summary

Cure Genetics is a Biotech company based in Suzhou, China, founded in 2016. It has raised $77.0M in total across 2 rounds, most recently a $60.0M Series B round in Jan 2022. Investors include Advantech Capital and Qiming VP.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJan 2022
$60.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cure Genetics on Indexed.vc
<a href="https://indexed.vc/companies/cure-genetics"><img src="https://indexed.vc/api/badge/company/cure-genetics" alt="Cure Genetics on Indexed.vc" width="260" height="76" /></a>